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To the Editor
The t(9;22) translocation results in the expression of the
constitutively active BCR-ABL1 tyrosine kinase. It is
detected in chronic myelogenous leukemia (CML) and in
~30% of adult acute lymphoblastic leukemia (ALL) patients
[1]. Thus, Ph+ ALL is not only the largest genetically
deﬁned subgroup of ALL, but also characterized by a poor
prognosis [2]. The two major protein isoforms of Bcr-Abl
are p210 and p190. Whereas the shorter p190 isoform is
speciﬁc for Ph+ ALL, the longer p210 isoform causes CML,
but is also present in ~30% of Ph+ ALL patients [1, 3].
BCR-ABL1 was the ﬁrst oncogene targeted successfully
with the tyrosine kinase inhibitor (TKI) imatinib, which
results in durable remissions in most CML patients and
increased remission rates and survival in Ph+ ALL patients.
Still, resistance to imatinib occurs particularly frequently in
Ph+ ALL. Several next-generation TKIs were developed to
address TKI resistance and intolerance [4]. Various TKI
resistance mechanisms, including dozens of Bcr-Abl
mutations, were described, but causes for resistance are
still elusive in a signiﬁcant portion of patients [5].
Deregulation of protein tyrosine phosphatases (PTP)
plays an important role in maintaining a wide range of
cancers. The ability of tyrosine phosphatases to antagonize
oncogenic tyrosine kinases makes them candidate tumor
suppressors. We previously showed that deregulation of
PTP1B causes resistance in Ph+ leukemias [6]. The phos-
phatase Sts-1 (suppressor of T-cell receptor signaling 1,
encoded by the human UBASH3B gene) was found to be
transcriptionally upregulated in Ph+ ALL as compared with
Ph− ALL patients [7]. Notably, Sts-1 also is one of the most
prominent interactors of Bcr-Abl as determined by a sys-
tematic interaction proteomics screen [8]. In two recent
independent studies, Sts-1 was found to interact
more strongly with the Bcr-Abl p210 isoform than with
p190 and to be phosphorylated in Bcr-Abl expressing cells
[9, 10]. Sts-1 and its only human and mouse paralogue, Sts-
2 (UBASH3A), comprise an N-terminal ubiquitin-asso-
ciated (UBA) domain, an Src homology 3 (SH3) domain
and a C-terminal phosphoglycerate mutase (PGM) domain,
which has structural homology with the histidine phos-
phatase superfamily. It was demonstrated that Sts-1 (and to
a lesser extent Sts-2) possesses tyrosine phosphatase
activity [11]. Strikingly, Sts-1 is a negative regulator of
several tyrosine kinase pathways, including not only EGFR
and PDGFR, but also ZAP-70 and SYK, thereby antag-
onizing T- and B-cell receptor signaling, respectively [12,
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13]. As genetic and functional perturbation of kinase–
phosphatase networks have been implicated in oncogenesis
and based on our previous expression and proteomics data,
we reasoned that the interaction between the Bcr-Abl kinase
and the Sts-1 phosphatase may contribute to leukemogen-
esis. We therefore investigated the functional relationship
between these two proteins, in particular the ability of Sts-1
to dephosphorylate Bcr-Abl and how it may contribute to
TKI resistance in Ph+ ALL patients.
To study the interaction of Bcr-Abl p190 with Sts-1 and
its dependence on kinase activity in Ph+ ALL cells, we
performed coimmunoprecipitation (co-IP) assays of the
endogenous p190 and Sts-1 in Sup-B15 cells either in the
absence or presence of imatinib. Sts-1 binding to p190 was
largely independent of the Bcr-Abl activation status, as their
interaction was only mildly reduced in cells following
exposure to imatinib (Fig. 1a). These data were conﬁrmed
by co-IP assays using murine Ba/F3 cells stably expressing
p190 or Sts-1 as an independent cell-line model. p190
interacted with endogenous or overexpressed Sts-1 regard-
less of the activation status of Bcr-Abl (Fig. 1b, c).
In order to map the interaction mode of the two proteins,
we ﬁrst determined if Sts-1 binds to the Bcr- or Abl-portion
of Bcr-Abl p190. These experiments were performed in Ba/
F3 cells upon coexpression of Sts-1 with full-length Bcr-
Abl, the Abl-portion (#ABL1) only, the Bcr oligomerization
domain directly fused to the Abl-portion (BCC-ABL1) or
only the Bcr-portion (BCR; Fig. 1d). These experiments
showed that Sts-1 binding was mediated by the Abl-portion
of Bcr-Abl, as all Abl-containing constructs, but not the
Bcr-portion alone, bound Sts-1 (Fig. 1d). To map the Sts-1
domains that are required for binding, we performed co-IP
assays using loss-of-function point mutations in all domains
of Sts-1, including the UBA (W72E), SH3 (W295A), and
PGM (H391A) domains (Fig. 1e). To further delineate the
requirements for binding to Bcr-Abl, we also assayed these
mutants in combination with Bcr-Abl mutants with either
abolished kinase activity (ΔK; D382N mutation) or a
deletion in the C-terminal last exon region (ΔLE). Sts-1
interacted with the N-terminal part of the Abl-portion of
Bcr-Abl encompassing the SH3-SH2-kinase domain unit
(Fig. 1e). This interaction was independent of the activation
status and the various protein–protein interaction motifs in
the C-terminal last exon region of Bcr-Abl. Furthermore,
the interaction does not require a functional UBA-, SH3-, or
PGM-domain of Sts-1 (Fig. 1e).
To study a possible functional interdependence of the
Bcr-Abl/Sts-1 kinase–phosphatase interaction, we ﬁrst
investigated how Sts-1 may regulate Bcr-Abl kinase activity
and autophosphorylation at different tyrosine (Y) residues:
Y177 in the Bcr-portion is critical for Ras-MAPK signaling,
whereas Y245 and Y412 in the Abl-portion are important
markers for kinase activation [14]. Thus, we examined the
autophosphorylation of Bcr-Abl in Ba/F3 cells in the pre-
sence and absence of Sts-1. In line with its binding prop-
erties, Sts-1 caused strong dephosphorylation of Bcr-Abl at
Abl-Y245 and Abl-Y412, whereas Bcr-Y177 was only
mildly dephosphorylated (Fig. 1f). In a second step, we
cotransfected HEK293 cells with either Bcr-Abl or an
oligomerization-deﬁcient mutant (ΔCC-Bcr-Abl) together
with either wild-type or a phosphatase-dead (H391A) Sts-1
[11]. We found that Sts-1 dephosphorylates both Bcr-Abl
and itself, and that Sts-1 is a kinase substrate of Bcr-Abl. In
fact, Sts-1 dephosphorylated Bcr-Abl and ΔCC-Bcr-Abl
strongly and equally well (Fig. 1g). Conversely, only
phosphatase-dead Sts-1, but not wild-type Sts-1, was
strongly phosphorylated in the presence of Bcr-Abl,
demonstrating that Sts-1 is able to dephosphorylate itself
(Fig. 1g).
Given that Sts-1 may regulate kinase activity of Bcr-Abl
by modulating its autophosphorylation, we next investi-
gated whether Sts-1 impacts on cell proliferation in IL-3-
independent Ba/F3 cells expressing wild-type (wt) Bcr-Abl
or the gatekeeper mutation T315I, which conveys resistance
to multiple TKIs. These cells were retrovirally transduced
with GFP or Sts-1-GFP, and proliferation competition
assays were performed over the course of 12 days. The
expression of GFP alone did not alter the proliferation of
BCR-ABL expressing Ba/F3 cells as revealed by the con-
stant percentage of GFP positive cells (Fig. 2a). In contrast,
expression of Sts-1-GFP reduced the proliferation of Ba/F3
cells expressing Bcr-Abl wt and T315I. Concomitant
treatment with 1 µM imatinib further decreased proliferation
of Bcr-Abl wt, but, as expected, not Bcr-Abl-T315I cells
(Fig. 2a). These results indicate that Sts-1 activity nega-
tively regulates cell proliferation induced by Bcr-Abl wt and
T315I.
To assess the role of Sts-1 in Bcr-Abl-driven leukemo-
genesis, we examined the induction of Bcr-Abl p210-
induced CML-like disease in wt vs. Sts-1/Sts-2 double-
knockout bone marrow cells using a transduction/trans-
plantation model. The absence of Sts-1/Sts-2 decreased the
survival of recipient mice signiﬁcantly and further aggra-
vated the pronounced splenomegaly observed in mice
transplanted with Bcr-Abl-expressing wt cells (Fig. 2b).
These results indicate that Sts-1/Sts-2 are functionally
relevant negative regulators of Bcr-Abl-dependent leuke-
mogenesis in a CML mouse model.
The glucocorticoid dexamethasone and Sts-1 seem to
regulate several common signaling pathways: Both inhibit
T-cell receptor (TCR) signaling by regulating TCR
expression and Sts-1 additionally inhibits certain down-
stream effectors [15]. In order to harness the therapeutic
potential of Sts-1’s ability to inhibit growth of Bcr-Abl-
positive cells, we explored whether dexamethasone may
alter Sts-1 expression and activity. Exposure of Sup-B15
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and Sup-B15RT cells to clinically relevant concentrations
of dexamethasone increased Sts-1 expression over time,
accompanied by decreased Bcr-Abl autophosphorylation in
Sup-B15 cells (Fig. 2c, d), indicating that it increases the
sensitivity of Bcr-Abl-transformed cells to TKIs. In cell
proliferation assays, concomitant treatment with dex-
amethasone and imatinib showed stronger inhibition than
each drug alone in both Sup-B15 and Sup-B15RT cells
(Fig. 2e).
Deregulation of the tyrosine phosphatase Sts-1 may be an
important and pharmacologically targetable mechanism for
Bcr-Abl mutation-independent resistance. Upregulation of
Sts-1 in Ph+ ALL together with its direct interaction with
both p190 and p210 Bcr-Abl strongly suggests a functional
Fig. 1 The Sts-1 phosphatase interacts with and dephosphorylates Bcr-
Abl. a SupB15 was treated with imatinib (2 µM for 6 h). ABL1
immunoprecipitates (left panel) from total cell lysates and 5% input
fraction (right panel) were immunoblotted with the indicated anti-
bodies. b Ba/F3 cells transduced with STS-1 were additionally trans-
duced with BCR-ABL1 and treated with imatinib (1 µM for 6 h). STS-
1 immunoprecipitates (right panel) from total cell lysates and 5% input
fraction (left panel) were immunoblotted with the indicated antibodies.
c Ba/F3 cells transduced with BCR-ABL1 were additionally trans-
duced with STS-1 and treated with imatinib (1 µM for 6 h). ABL1
immunoprecipitates (right panel) from total cell lysates and 5% input
fraction (left panel) were immunoblotted with the indicated antibodies.
d Ba/F3 cells transduced with full-length Bcr-Abl, the Abl-portion
(#ABL1) only, the Bcr oligomerization domain directly fused to the
Abl-portion (BCC-ABL1) or only the Bcr-portion (BCR) was addi-
tionally transduced with STS-1. ABL1 (upper panels) and STS-1
(lower panels) immunoprecipitates from total cell lysates were
immunoblotted with the indicated antibodies. e HEK293 cells were
cotransfected with BCR-ABL1 wt, Bcr-Abl kinase-dead (D382N;
BCR-ABLΔK) or BCR-ABL1 lacking the C-terminal last exon region
(BCR-ABLΔLE) with STS-1 wt and point mutations in functional
domains (UBA (W72E), SH3 (W295A), and PGM (H391A)). ABL1
immunoprecipitates were analyzed by immunoblotting using the
indicated antibodies. f Ba/F3 cells retrovirally expressing BCR-ABL1
were transfected with STS-1 or empty vector. Whole-cell lysates were
then analyzed with the indicated antibodies. g HEK293 cells were
cotransfected with BCR-ABL1 wt or an oligomerization-defective
BCR-ABL1 lacking the coiled-coil domain (ΔCC-BCR-ABL1) with
either STS-1 wt or a phosphatase-dead STS-1 mutant (H391A). Total
cell lysates were analyzed by immunoblotting using the indicated
antibodies
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deregulation of protein phosphorylation similar to that we
previously showed for PTP1B [6]. The fact that its normal
function can be restored by ectopic overexpression not only
indicates a central role for Sts-1 in the regulation of Bcr-Abl
but also that the deregulation of Sts-1 is based on a loss of
balance between Bcr-Abl kinase and Sts-1 phosphatase
activity. This establishes the upregulation of Sts-1 by drugs,
such as dexamethasone, as a valid therapeutic approach for
increasing the sensitivity to TKIs.
In conclusion, we delineated the molecular interaction
mode of the Sts-1 phosphatase with the Bcr-Abl kinase and
provide strong evidence that Sts-1 is a negative regulator of
Bcr-Abl signaling, cell proliferation, and leukemogenesis.
In addition, the parallel study by Udainiya et al. (cosub-
mitted) shows a broad impact of Sts-1 on the Bcr-Abl
phosphoproteome network and precisely delineated the Sts-
1 interactome using quantitative functional proteomics
techniques. Furthermore, we show that modulation of Sts-1
expression by dexamethasone inﬂuences TKI sensitivity of
Ph+ ALL cells. Therefore, the inclusion of dexamethasone
for therapy regimens in Ph+ ALL for may increase sensi-
tivity to TKIs by upregulating Sts-1.
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Fig. 2 Sts-1 negatively regulates Bcr-Abl-dependent leukemogenesis
and cell proliferation and its expression is upregulated by dex-
amethasone. a The proliferation competition assay with Ba/F3 cell
transduced with BCR-ABL1 wt or T315I in the absence or presence of
STS-1 expression and without (left) or with (right) imatinib treatment
(2 µM). BCR-ABL1-positive cells are marked with GFP and the
relative changes in GFP expression were measured by FACS and
followed over time. Mean values ± SD from three replicates are shown.
b Equal amounts of primary murine Lin− c-Kit+ Sca-1+ cells from wt
or Sts-1/Sts-2 knockout animals expressing BCR-ABL1 were injected
in lethally irradiated recipient mice (n= 8 for each group). Overall
survival of transplanted mice was monitored over 60 days. P-value=
0.014 was calculated using a logrank (Mantel–Cox) test. Representa-
tive spleens from control mice, BCR-ABL1/Sts-1/2 wt and BCR-
ABL1/Sts-1/2 KO mice are shown. c SupB15 Ph+ ALL cells and their
imatinib-resistant subline SupB15RT were exposed to 10−7 M dex-
amethasone, and STS-1 expression was investigated at the given time
points. α-Tubulin was used as loading control. d SupB15 Ph+ ALL
cells and their imatinib-resistant subline SupB15RT were exposed to
10−7M dexamethasone, and the effect of increasing expression of STS-
1 on BCR-ABL1 phosphorylation was investigated by an anti-p-Tyr
antibody. e SupB15 and SupB15RT were exposed to imatinib (1 µM)
and 10−7M dexamethasone alone or in combination and proliferation
was analyzed by the XTT assay. The bars represent the mean (±SEM)
of three independent experiments, each performed in triplicates. Sta-
tistical signiﬁcance was calculated using student’s t test. ***p ≤ 0.001
A. A. Mian et al.
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Deininger MW, Goldman JM, Melo JV. The molecular biology of
chronic myeloid leukemia. Blood. 2000;96:3343–56.
2. Ottmann OG, Pfeifer H Management of Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Hematol Am Soc Hematol Educ Program. 2009;1:371–81.
3. Reckel S, Gehin C, Tardivon D, Georgeon S, Kukenshoner T,
Lohr F, et al. Structural and functional dissection of the DH and
PH domains of oncogenic Bcr-Abl tyrosine kinase. Nat Commun.
2017;8:2101.
4. Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of
ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer
Res. 2012;72:4890–5.
5. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the
limits of targeted therapy in chronic myeloid leukaemia. Nat Rev
Cancer. 2012;12:513–26.
6. Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J,
Myloch S, et al. Inhibition of phosphotyrosine phosphatase
1B causes resistance in BCR-ABL-positive leukemia cells to
the ABL kinase inhibitor STI571. Clin Cancer Res. 2006;12:
2025–31.
7. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe
JM, et al. Differential gene expression patterns and interaction
networks in BCR-ABL-positive and -negative adult acute lym-
phoblastic leukemias. J Clin Oncol. 2007;25:1341–9.
8. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M,
Kocher T, et al. Charting the molecular network of the drug target
Bcr-Abl. Proc Natl Acad Sci USA. 2009;106:7414–9.
9. Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe
D, et al. Differential signaling networks of Bcr-Abl p210 and p190
kinases in leukemia cells deﬁned by functional proteomics. Leu-
kemia. 2017;31:1502–12.
10. Cutler JA, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S,
Nirujogi RS, et al. Differential signaling through p190 and p210
BCR-ABL fusion proteins revealed by interactome and phos-
phoproteome analysis. Leukemia. 2017;31:1513–24.
11. Mikhailik A, Ford B, Keller J, Chen Y, Nassar N, Carpino N. A
phosphatase activity of Sts-1 contributes to the suppression of
TCR signaling. Mol Cell. 2007;27:486–97.
12. Carpino N, Turner S, Mekala D, Takahashi Y, Zang H, Geiger TL,
et al. Regulation of ZAP-70 activation and TCR signaling by two
related proteins, Sts-1 and Sts-2. Immunity. 2004;20:37–46.
13. Raguz J, Wagner S, Dikic I, Hoeller D. Suppressor of T-cell
receptor signalling 1 and 2 differentially regulate endocytosis and
signalling of receptor tyrosine kinases. FEBS Lett.
2007;581:4767–72.
14. Hantschel O. Structure, regulation, signaling, and targeting of abl
kinases in cancer. Genes Cancer. 2012;3:436–46.
15. Migliorati G, Bartoli A, Nocentini G, Ronchetti S, Moraca R,
Riccardi C. Effect of dexamethasone on T-cell receptor/CD3
expression. Mol Cell Biochem. 1997;167:135–44.
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis
